Business
GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed Continued momentum with completed patient enrollment for the 6-week interim analysis (N=24) and over two-thirds enrollment completed for the overall trial Results on track for interim data in Q2 2025 and topline data in Q3 2025 Management releases “What This Means” segment discussing the interim biomarker data; Access Here LA JOLLA, CA, May 0
About this update from Gri Bio, Inc.
[{"type":"image","alt":"GRI Bio, Inc.","displaySize":"","headline":null,"caption":"GRI Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":298,"height":144,"url":"https://media.zenfs.com/en/globenewswire.com/54d4b237b8db6f5a566b8418ca0ae02c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VpQzftFLIZDIqhYm6TSWfw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/54d4b237b8db6f5a566b8418ca0ae02c","width":298,"height":144}},"lazy":false},{"type":"text","content":"The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed","length":155,"tagName":"p"},{"type":"text","content":"Continued momentum with completed patient enrollment for the 6-week interim analysis (N=24) and over two-thirds enrollment completed for the overall trial","length":154,"tagName":"p"},{"type":"text","content":"Results on track for interim data in Q2 2025 and topline data in Q3 2025","length":72,"tagName":"p"},{"type":"text","content":"Management releases “What This Means” segment discussing the interim biomarker data; Access Here","length":96,"tagName":"p"},{"type":"text","content":"LA JOLLA, CA, May 08, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported interim biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”). Additionally, management participated in a Virtual Investor “What This Means” segment to discuss the interim biomarker data. The segment is now available here.","length":587,"tagName":"p"},{"type":"text","content":"The IDMC has examined the change from baseline biomarkers from the first 12 subjects at 2 weeks and determined the change from baseline in PRO-C3 of GRI-0621-treated patients compared to placebo patients is suggestive of anti-fibrotic effect. Based on the available interim data reviewed, the IDMC has recommended the Phase 2a study evaluating GRI-0621 to continue as planned as there are no safety concerns seen to date.","length":421,"tagName":"p"},{"type":"text","content":"“While still early and in a small...